Sanofi Stock Price Change Within One Week After FDA Decision on Dupixent | Categorical | | | 7 months ago | |
Dupixent's Ranking Among Top-Selling Drugs Worldwide in 2024 | Categorical | | | 7 months ago | |
FDA Approval of Dupixent for COPD by September 27, 2024? | Binary | | | 7 months ago | |
Will Dupixent sales grow in Q4 2024? | Binary | | | 7 months ago | |
Will Dupixent receive additional approvals for new indications by end of 2024? | Binary | | | 7 months ago | |
Market Share of Dupixent in COPD Treatments in Europe by end of 2024 | Categorical | | | 7 months ago | |
Will Eylea retain majority market share over its biosimilars by May 2025? | Binary | | | 7 months ago | |
Financial impact on Regeneron after the launch of Eylea biosimilars by Q2 2025 | Categorical | | | 7 months ago | |
Medical community's reception to Eylea biosimilars by 2025 | Categorical | | | 7 months ago | |
Will Regeneron's stock price increase due to the launch of Eylea biosimilars by the end of 2024? | Binary | | | 7 months ago | |
Expansion of Regeneron-Mammoth Partnership Beyond CRISPR by 2025 | Binary | | | 8 months ago | |
Number of New Diseases Targeted by Regeneron-Mammoth by 2025 | Categorical | | | 8 months ago | |
Outcome of First Regulatory Review for Regeneron-Mammoth CRISPR Therapy by 2026 | Categorical | | | 8 months ago | |
Regeneron Increases Equity in Mammoth by 2026 | Binary | | | 8 months ago | |
First Disease Targeted for CRISPR Therapy by Regeneron-Mammoth | Categorical | | | 8 months ago | |
First Disease Targeted by Regeneron-Mammoth CRISPR Collaboration | Categorical | | | 8 months ago | |
Regeneron Outperformance of S&P 500 by End of 2024 | Binary | | | 8 months ago | |
First Human Trials of Regeneron-Mammoth CRISPR Therapy by 2025 | Binary | | | 8 months ago | |
Regeneron Milestone Payment to Mammoth by End of 2024 | Binary | | | 8 months ago | |
Greater Revenue Growth in 2024: Regeneron vs Mammoth Biosciences | Categorical | | | 8 months ago | |
FDA Approval of Regeneron-Mammoth CRISPR Therapies by 2027 | Categorical | | | 8 months ago | |
First gene therapy product announced by Regeneron and Mammoth by 2026? | Binary | | | 8 months ago | |
Significant gene editing research milestone achieved by Regeneron and Mammoth in the first year | Categorical | | | 8 months ago | |
First type of disease targeted by Regeneron and Mammoth partnership | Categorical | | | 8 months ago | |
New Gene Editing Enzyme Patent by 2024 | Binary | | | 8 months ago | |
First CRISPR Therapy Development by 2025 | Binary | | | 8 months ago | |
Regeneron Ups Investment in Mammoth by 2025 | Binary | | | 8 months ago | |
Number of CRISPR Therapies by 2026 | Categorical | | | 8 months ago | |
First Disease Target for CRISPR Therapy | Categorical | | | 8 months ago | |
Success Rate of Initial CRISPR Clinical Trials by 2027 | Categorical | | | 8 months ago | |
First Commercial Region for Regeneron-Mammoth CRISPR Therapy | Categorical | | | 8 months ago | |
Regeneron-Mammoth CRISPR Therapy Clinical Trials by 2025? | Binary | | | 8 months ago | |
Regeneron Increases Investment in Mammoth by 2026? | Binary | | | 8 months ago | |
FDA Approval for Regeneron-Mammoth CRISPR Therapy by 2028? | Binary | | | 8 months ago | |
First Disease Target for Regeneron-Mammoth CRISPR Trials | Categorical | | | 8 months ago | |
First CRISPR-Based Product Type from Regeneron-Mammoth | Categorical | | | 8 months ago | |
Will Biocon and Biogen's biosimilars be launched in the US market by the end of 2024? | Binary | | | 7 months ago | |
Market share competition between Biocon and Biogen's Eylea biosimilars by 2025 | Categorical | | | 7 months ago | |
Successful Phase 1 CRISPR Trial by End of 2025 | Binary | | | 8 months ago | |
Regeneron and Mammoth partnership terminated by 2027? | Binary | | | 8 months ago | |
Regeneron stock price increases by over 15% within one year due to Mammoth investment? | Binary | | | 8 months ago | |
Financial status of Mammoth Biosciences one year after Regeneron's investment | Categorical | | | 8 months ago | |
